Gilead Sciences, Inc. announced that the Phase III ENHANCE study in higher-risk myelodysplastic syndromes has been discontinued due to futility based on a planned analysis. The safety data seen in this study is consistent with the known magrolimab profile and adverse events that are typical in this patient population.
[Gilead Sciences, Inc. (BusinessWire, Inc.)]
